RESEARCH-USE BIOSIMILAR ANTIBODY

Bexmarilimab

Monoclonal antibody · IgG4

STAB1IgG4RUO

Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma.

TARGETSTAB1
YMonoclonal antibody
CATALOGSC-BS-718
CATALOG NUMBERSC-BS-718
MOLECULAR WEIGHTApprox. 146.22 kDa
PRODUCT FORMATMonoclonal antibody

A research-use configuration for comparative antibody studies

Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma.

Bexmarilimab is a recombinant research-use antibody directed against STAB1.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte
Bexmarilimab | StellaCyte